Governor J.B. Pritzker has publicly disclosed that he has been using a GLP-1 medication since receiving a Type 2 diabetes diagnosis two years ago, offering a rare glimpse into how high-profile individuals manage the chronic condition. The revelation comes as weight-loss drugs like Ozempic and Wegovy—both GLP-1 agonists—have surged in popularity, sparking debates over accessibility, side effects, and their role in diabetes care. While the governor’s disclosure sheds light on personal health choices, it also raises questions about the broader implications of these treatments for patients nationwide. The announcement may prompt discussions on medication transparency among public figures and the evolving landscape of diabetes management.
The Illinois governor reveals he’s been on a GLP-1 since being diagnosed with Type 2 diabetes two years ago.
